BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11686505)

  • 1. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography.
    Hauser M; Gibson BS; Wilson N
    Eur J Pediatr; 2001 Oct; 160(10):607-10. PubMed ID: 11686505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.
    Moon TJ; Miyamoto SD; Younoszai AK; Landeck BF
    Cardiol Young; 2014 Oct; 24(5):854-65. PubMed ID: 24044518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H; Nielsen G
    Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
    Elbl L; Hrstkova H; Tomaskova I; Michalek J
    Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
    Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
    J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical performance in long-term survivors of acute leukaemia in childhood.
    Black P; Gutjahr P; Stopfkuchen H
    Eur J Pediatr; 1998 Jun; 157(6):464-7. PubMed ID: 9667400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
    Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
    Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamic stress echocardiography in asymptomatic patients treated for malignant diseases in childhood].
    Elbl L; Hrstková H; Chaloupka V; Novotný J
    Vnitr Lek; 2003 Apr; 49(4):273-9. PubMed ID: 12793049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy.
    Kumar S; Marfatia R; Tannenbaum S; Yang C; Avelar E
    Tex Heart Inst J; 2012; 39(3):424-7. PubMed ID: 22719160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of stress echocardiography and radionuclide ventriculography in the diagnosis of cardiomyopathy in patients receiving chemotherapy for malignant diseases].
    Leischik R; Eising EG; Katz M; Glattki G; Bruch C; Seeber S; Bockisch A; Erbel R
    Dtsch Med Wochenschr; 1997 Dec; 122(49):1509-15. PubMed ID: 9453916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy.
    Cheung YF; Hong WJ; Chan GC; Wong SJ; Ha SY
    Heart; 2010 Jul; 96(14):1137-41. PubMed ID: 20511624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of Myocardial function during therapy with cardiotoxic cytostatics. Studies with the example of anthracycline-containing chemotherapy].
    Richter-v Arnauld HP; Kleeberg UR; Hassel C; Spehn J; Erdmann H
    Onkologie; 1982 Aug; 5(4):168-73. PubMed ID: 6755329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.